Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Abbenante MC"'
Autor:
Bocchia M, Carella AM, Mulè A, Rizzo L, Turrini M, Abbenante MC, Cairoli R, Calafiore V, Defina M, Gardellini A, Luzi G, Patti C, Pinazzi MB, Riva M, Rossi G, Sammartano V, Rigacci L
Publikováno v:
Pharmacogenomics and Personalized Medicine, Vol Volume 15, Pp 393-407 (2022)
Monica Bocchia,1 Angelo Michele Carella,2 Antonino Mulè,3 Lorenzo Rizzo,4 Mauro Turrini,5 Maria Chiara Abbenante,2 Roberto Cairoli,4 Valeria Calafiore,3 Marzia Defina,1 Angelo Gardellini,5 Giovanni Luzi,6 Caterina Patti,3 Maria Beatrice Pinazzi,6 Ma
Externí odkaz:
https://doaj.org/article/2013b01b34394460868b78e8a6e720fb
Autor:
GHELLI LUSERNA DI RORÀ, ANDREA, IACOBUCCI, ILARIA, FERRARI, ANNA, LONETTI, ANNALISA, Papayannidis, C, Derenzini, E, Venturi, C, Imbrogno, E, Abbenante, Mc, Perricone, M, Robustelli, V, Guadagnuolo, V, Vitale, A, Elia, L, Musuraca, G, Ronconi, S, Carloni, S, Ottaviani, E, Paolini, S, Parisi, S, Sartor, C, Cattina, F, Russo, D, Martinelli, G.
The activation of Chk1 has been demonstrated to influence response to chemotherapy in patients with BCR-ABL-positive chronic myeloid leukemia patients (Nieborowska-Skorska et al, Cell Cycle 2006). Chk1 and Chk2 are serine threonine kinase activated b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4094::0fceea089a3a5cfcfd51c74de02764b0
http://hdl.handle.net/11585/604858
http://hdl.handle.net/11585/604858
Autor:
Clissa C, Stanzani M, Curti A, PAOLINI, STEFANIA, PAPAYANNIDIS, CRISTINA, Parisi S, Abbenante MC, Bosi C, FINELLI, CARLO, FOLLO, MATILDE YUNG, MONGIORGI, SARA, MANZOLI, LUCIA, MARTINELLI, GIOVANNI, COCCO, LUCIO ILDEBRANDO, CAVO, MICHELE
Azacitidine (AZA) has proven effective in Myelodysplastic Syndromes (MDS), and the currently approved AZA regimen is 75 mg/sqm/die subcutaneously for 7 days every 28 days. Subsequently, other alternative and more convenient AZA dosing regimens have s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4094::6512780e2ad8fe05a85f8a31bfc604c2
http://hdl.handle.net/11585/396800
http://hdl.handle.net/11585/396800
Autor:
Clissa C, Curti A, PAOLINI, STEFANIA, PAPAYANNIDIS, CRISTINA, Parisi S, Abbenante MC, Bosi C, FINELLI, CARLO, FOLLO, MATILDE YUNG, MONGIORGI, SARA, MANZOLI, LUCIA, MARTINELLI, GIOVANNI, COCCO, LUCIO ILDEBRANDO, BACCARANI, MICHELE
Introduction. Azacitidine (AZA) has proven effective in myelodysplastic syndromes (MDS). The duration of haematological response is limited (median 13.6 months) (Fenaux, 2009), although some patients (pts) show a prolonged response. These data prompt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4094::7908ce49b14f29dc331875a681315c2b
http://hdl.handle.net/11585/396770
http://hdl.handle.net/11585/396770
Autor:
FINELLI, CARLO, FOLLO, MATILDE YUNG, MONGIORGI, SARA, MARTINELLI, GIOVANNI, COCCO, LUCIO ILDEBRANDO, BACCARANI, MICHELE, Clissa C, Curti A, PAOLINI, STEFANIA, PAPAYANNIDIS, CRISTINA, Stoni N, Parisi S, Abbenante MC, Marzocchi G
Introduction. Erytropoiesis-stimulating agents (ESAs) are effective in 20-30% of patients (pts) with Myelodysplastic Syndromes (MDS), but response rates are higher when pts are selected on the basis of clinical and hematologic parameters: baseline se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4094::1e0e286529fee39c2937db871fba52d4
http://hdl.handle.net/11585/396778
http://hdl.handle.net/11585/396778
Autor:
Iacobucci I, Cattina F, Pomella S, Brighenti E, Papayannidis C, Derenzini E, Lonetti A, Ferrari A, Verga Falzacappa MV, Guadagnuolo V, Aluigi M, Ottaviani E, Abbenante MC, Soverini S, Russo D, Pelicci PG, Baccarani M, Martinelli G
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4094::b5220002937b6967cb349d135e7397bb
http://hdl.handle.net/11585/144071
http://hdl.handle.net/11585/144071
Autor:
PAPAYANNIDIS, CRISTINA, IACOBUCCI, ILARIA, LONETTI, ANNALISA, OTTAVIANI, EMANUELA, TESTONI, NICOLETTA, BALDAZZI, CARMEN, CURTI, ANTONIO, PAOLINI, STEFANIA, CLISSA, CRISTINA, MARTINELLI, GIOVANNI, Abbenante MC, Guadagnuolo V, Ferrari A, Parisi S, Baccarani M
Background. Nelarabine (N) is approved for the treatment of T-ALL and T-LBL that have not responded to or has relapsed after treatment with at least 2 chemotherapy regimens. Aim. To evaluate safety profile and efficacy of N as savage therapy in 16 ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4094::5b3fba22f89535fed1aacbc1d2674f9d
http://hdl.handle.net/11585/154794
http://hdl.handle.net/11585/154794
Autor:
Papayannidis, C, Iacobucci, I, Candoni, A, Abbenante, Mc, Paolini, S, Malagola, Michele, Ottaviani, E, Lonetti, A, Curti, A, Parisi, S, Testoni, N, Lama, B, Maccarani, M, Martinelli, G.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3662::b1a4848cee838d310ff424a235d2c0b5
http://hdl.handle.net/11379/218503
http://hdl.handle.net/11379/218503
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Annalisa Lonetti, Francesca Paoloni, Antonella Vitale, Maria Chiara Abbenante, Leonardo Potenza, Fabrizio Pane, Robin Foà, Clelia Tiziana Storlazzi, Ilaria Iacobucci, Emanuela Ottaviani, Anna Maria Ferrari, Marco Vignetti, Michele Baccarani, Luciana Impera, Giovanni Martinelli, Stefania Paolini, Stefania Trino, Simona Soverini, Federica Cattina, Cristina Papayannidis, Mario Luppi
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 17(23)
Purpose: The 9p21 locus, encoding three important tumor suppressors (p16/CDKN2A, p14/ARF, and p15/CDKN2B), is a major target of inactivation in the pathogenesis of many human tumors. Patients and Methods: To explore, at high resolution, the frequency
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b0f29a923a30e66659a0753d0e7db0f
https://pubmed.ncbi.nlm.nih.gov/22134481
https://pubmed.ncbi.nlm.nih.gov/22134481